Addition of methotrexate to regain clinical response in IBD patients on anti-TNF therapy
Methotrexate to suppress immunogenicity to anti-tumor necrosis factor therapy in IBD patients with loss of response Methotrexate to suppress immunogenicity to anti-tumor necrosis factor therapy in IBD patients with l ...
Trade Name: methotrexate injection INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Trade Name: methotrexate injection INN or Proposed INN: Methotrexate Other descriptive name: METHOTREX ...
Amsterdam UMC location AMC
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
60
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...
Addition of methotrexate to regain clinical response in IBD patients on anti-TNF therapy
Methotrexate to suppress immunogenicity to anti-tumor necrosis factor therapy in IBD patients with loss of response Methotrexate to suppress immunogenicity to anti-tumor necrosis factor therapy in IBD patients with l ...
Trade Name: methotrexate injection INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Trade Name: methotrexate injection INN or Proposed INN: Methotrexate Other descriptive name: METHOTREX ...
Amsterdam UMC location AMC
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
60
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...